We further examined the effects of Taxifolin on hepatic steatosis and found that serum concentrations of AST and ALT, along with the hepatic contents of triglyceride and MDA, were dose-dependently reduced by Taxifolin treatment (Figure 2A–C). This evidence concerns the gene GPT and fatty liver disease.